Use of Dupilumab and Eosinophil Targeted Therapy in Treating Angiolymphoid Hyperplasia With Eosinophilia

JAMA Dermatol. 2022 Aug 1;158(8):960-962. doi: 10.1001/jamadermatol.2022.1969.

Authors

Kathryn Franke¹, Eliza Notaro², Ata S Moshiri^{3

4}, Andrew Ayars⁵, Andrea Kalus³

Affiliations

¹ University of Washington School of Medicine, Seattle.
² Dermatology, The Polyclinic, Seattle, Washington.
³ Division of Dermatology, Department of Medicine, University of Washington School of Medicine, Seattle.
⁴ Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
⁵ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle.

PMID: 35675071
DOI: 10.1001/jamadermatol.2022.1969

No abstract available

MeSH terms

Angiolymphoid Hyperplasia with Eosinophilia* / diagnosis
Angiolymphoid Hyperplasia with Eosinophilia* / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use
Castleman Disease*
Eosinophils
Humans

Substances

Antibodies, Monoclonal, Humanized
dupilumab